What Do FVC and DLCO Mean on Your ILD PFT Results?
At a Glance
FVC measures how much air you can force out, while DLCO estimates how well gas moves from the lungs into the blood. In ILD, doctors interpret both over time with symptoms, oxygen levels, lung capacity, and CT findings; one low result alone does not prove worsening.
In this answer
4 sections
When you receive your pulmonary function test (PFT) results for interstitial lung disease (ILD), the acronyms can look like an alphabet soup. Seeing numbers that are lower than you expect can be frightening, but it helps to know that these numbers are just one piece of the puzzle. The two commonly followed measures on these reports are FVC and DLCO.
By tracking these two numbers over time, your medical team can monitor how your lungs are functioning. However, doctors do not rely on FVC and DLCO alone; they combine them with other tests like Total Lung Capacity (TLC), oxygen levels, CT scans, and how you feel day-to-day to guide your care [1] [2].
What is FVC (Forced Vital Capacity)?
FVC stands for Forced Vital Capacity. This is the total amount of air you can forcefully and completely blow out after taking the deepest breath possible [3].
In ILD, scarring (fibrosis) or inflammation can make the lung tissue stiffer and less stretchy. Because the lungs cannot expand fully, they hold less air. A lower FVC number can be a clue that your lungs are restricted by the disease [3].
However, FVC does not directly measure the exact amount of scarring in your lungs. A low FVC can also be caused by how hard you try during the test, your respiratory muscle strength, airway disease, or other factors like obesity [4] [5]. To confirm true lung restriction, your doctor will often look at another measurement called Total Lung Capacity (TLC) [3].
What is DLCO (Diffusing Capacity for Carbon Monoxide)?
DLCO stands for Diffusing Capacity of the Lungs for Carbon Monoxide. During this part of the test, you inhale a small, carefully measured, safe amount of carbon monoxide and an inert tracer gas, hold your breath for about 10 seconds, and exhale [6].
This test estimates gas transfer capacity—how easily gases cross over from the tiny air sacs in your lungs (alveoli) into your bloodstream [6]. Because ILD damages the tissue where this gas exchange happens, a lower DLCO often means your lung’s gas transfer is impaired [3].
It is important to know that DLCO does not directly measure the oxygen levels in your blood; your oxygen saturation can be completely normal at rest even if your DLCO is low. Furthermore, a low DLCO is not only caused by ILD scarring. It can be heavily influenced by anemia (low red blood cell count), smoking, emphysema, or pulmonary hypertension (high blood pressure in the blood vessels of the lungs) [7] [8]. Your doctor should ideally look at your “hemoglobin-corrected” DLCO to account for anemia.
Reading Your Report: Percentages and Predictions
Your PFT report will usually show your FVC and DLCO as a percentage of predicted (e.g., “FVC 75% predicted”). This number compares your results to reference equations based on a healthy population of the same age, height, and birth sex [5].
Different laboratories sometimes use different reference equations to calculate this percentage. Because of this, it is always best to have your PFTs done at the same laboratory so the trends in your numbers are a true “apples-to-apples” comparison.
How Doctors Use Trends to Guide Treatment
Because ILD is an umbrella term for many different diseases, treatment goals vary. Some inflammatory types of ILD may improve with medication, while fibrotic (scarring) types of ILD are usually treated with antifibrotic drugs that aim to slow down the decline of your lung function, rather than increase your numbers [9].
When tracking your disease, doctors look for meaningful changes. Depending on the guideline or specific ILD, doctors use different thresholds as a sign of progression.
- Absolute vs. Relative Change: It is important to understand the difference between absolute and relative drops. If your FVC falls from 80% to 72% predicted, that is an 8 percentage-point absolute decline, but a 10% relative decline (because 8 is 10% of 80).
- Examples of Progression Thresholds: In some fibrotic ILDs, a warning sign of progression is a 10% relative drop in FVC over a year [10]. Broad guidelines for progressive pulmonary fibrosis sometimes look for an absolute FVC decline of 5 percentage points, or an absolute DLCO decline of 10 percentage points, combined with worsening symptoms or CT scan changes [11].
The Big Picture: Because day-to-day PFT results can fluctuate based on fatigue, recent illness, or testing effort, a single lower number does not automatically mean your disease is worsening [12]. Stabilization or a slower decline is often a realistic sign of treatment success [13] [14]. Never start, stop, or change your medications based on a single PFT number alone.
Safety Note: While gradual changes in your PFTs are tracked over months, sudden changes in how you feel require immediate attention. Seek urgent medical help if you experience severe sudden breathlessness, chest pain, fainting, blue lips, or dangerously low oxygen levels.
Common questions in this guide
What does FVC measure in an ILD pulmonary function test?
What does DLCO tell me about my ILD?
Does one low FVC or DLCO mean my ILD is getting worse?
What does percent predicted mean on my PFT report?
Why should my DLCO be corrected for hemoglobin?
How much do FVC or DLCO need to change before ILD is considered worse?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What are my FVC and DLCO absolute values and percentages, and how have they trended over my last few tests?
- 2.Are my DLCO results corrected for my hemoglobin levels?
- 3.If my DLCO is disproportionately low compared to my FVC, should we be screening for pulmonary hypertension or emphysema?
- 4.Based on my specific type of ILD, what threshold of change in my FVC or DLCO would prompt us to rethink my current treatment plan?
- 5.Do my other test results, like Total Lung Capacity (TLC) or my oxygen levels with exertion, show a different picture than my FVC and DLCO alone?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (14)
- 1
Underdetection of Interstitial Lung Disease in Juvenile Systemic Sclerosis.
Foeldvari I, Klotsche J, Hinrichs B, et al.
Arthritis care & research 2022; (74(3)):364-370 doi:10.1002/acr.24499.
PMID: 33141441 - 2
Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review.
Petelytska L, Bonomi F, Cannistrà C, et al.
RMD open 2023; (9(4)) doi:10.1136/rmdopen-2023-003426.
PMID: 37940340 - 3
Office-based DLCO tests help pulmonologists to make important clinical decisions.
Enright Md P
Respiratory investigation 2016; (54(5)):305-11.
PMID: 27566377 - 4
Chest wall muscle atrophy as a contributory factor for forced vital capacity decline in systemic sclerosis-associated interstitial lung disease.
Nawata T, Shirai Y, Suzuki M, Kuwana M
Rheumatology (Oxford, England) 2021; (60(1)):250-255 doi:10.1093/rheumatology/keaa322.
PMID: 32699895 - 5
Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases.
Ciancio N, Pavone M, Torrisi SE, et al.
Multidisciplinary respiratory medicine 2019; (14()):17 doi:10.1186/s40248-019-0179-2.
PMID: 31114679 - 6
The Reliability of a Novel Structured Testing Device for Single-breath Lung Carbon Monoxide Uptake: A Randomized Comparison Crossover Study.
Yao S, Fu T, Lin K, et al.
BMC pulmonary medicine 2025; (25(1)):230 doi:10.1186/s12890-025-03571-7.
PMID: 40349000 - 7
Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension.
Antoniou KM, Margaritopoulos GA, Goh NS, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2016; (68(4)):1004-12 doi:10.1002/art.39528.
PMID: 26636545 - 8
Navigating the Complexity of PH-ILD: From Molecular Mechanisms to Integrated Clinical Evaluation.
Vasarmidi E, Calaras D, Kourouni I, et al.
International journal of molecular sciences 2026; (27(15)) doi:10.3390/ijms27157055.
PMID: 42589704 - 9
Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics.
Kolb M, Flaherty KR, Silva RS, et al.
Advances in therapy 2023; (40(12)):5536-5546 doi:10.1007/s12325-023-02668-x.
PMID: 37751022 - 10
Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.
Goh NS, Hoyles RK, Denton CP, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2017; (69(8)):1670-1678 doi:10.1002/art.40130.
PMID: 28426895 - 11
Antifibrotic therapy in progressive pulmonary fibrosis: a review of recent advances.
Naqvi M, Hannah J, Lawrence A, et al.
Expert review of respiratory medicine 2024; (18(6)):397-407 doi:10.1080/17476348.2024.2375420.
PMID: 39039699 - 12
Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.
Hoffmann-Vold AM, Allanore Y, Alves M, et al.
Annals of the rheumatic diseases 2021; (80(2)):219-227 doi:10.1136/annrheumdis-2020-217455.
PMID: 32988845 - 13
Pulmonary Function and Radiographic Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease: A Systematic Review of Rituximab, Interleukin-6 Inhibitors, and Janus Kinase Inhibitors.
Patel RM, Chary N, Kesselman MM
Cureus 2026; (18(7)):e112918 doi:10.7759/cureus.112918.
PMID: 42610014 - 14
Long-term safety and pulmonary function stabilization with nintedanib in systemic sclerosis-associated interstitial lung disease, 2020-2025: a real-world retrospective study from a reference centre.
Panopoulos S, Poulia V, Vlachogiannis N, et al.
Rheumatology international 2026; (46(7)).
PMID: 42283879
This page is for informational purposes only and does not constitute medical advice. Your pulmonologist or care team should interpret your FVC, DLCO, and other test results in context.
Get notified when new evidence is published on Interstitial lung disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.